华佗品牌怎么样 申请店铺

我要投票 华佗在中草药行业中的票数:726 更新时间:2025-08-20
华佗是哪个国家的品牌?「华佗」是 华佗国药股份有限公司 旗下著名品牌。该品牌发源于安徽,由创始人李宏良在2009期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力华佗品牌出海!将品牌入驻外推网,定制华佗品牌推广信息,可以显著提高华佗产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

华佗怎么样

安徽华佗国药股份有限公司位于三朝古都,华佗故里,中国历史文化名城,全国四大药都之首—安徽省亳州市。安徽华佗国药股份有限公司已有50多年建厂历史,设计规模及生产能力居安徽前列,在全国也位列前茅;2001年又斥资上亿元,由省医药设计院,参照中外合资先进企业的优点和特色,经科学规划、精心设计、高标准建设、全面实施国家医药GMP工程,并于2002年12月8日一次性通过国家GMP认证,是国内第一批通过GMP认证的企业之一。

致力于发展传统的中医药文化,倡导安全用药,安心用药,秉承“用良心制好药”的理念,华佗国药厂自始就以质量控制为第一要务,厂内配有全进口日本岛津公司高效液相仪、气相色谱仪、薄层扫描仪、紫光分析仪等检测设备,堪称高起点,高标准的现代化中成药制造企业和中药材加工基地。厂内现有国内领先的全自动生产灌装线、自动颗粒包装机、自动胶囊填充机、自动铝塑包装机、全自动高效包衣机等现代化设备均完全符合国家GMP标准。并配有空压冷冻系统、净化系统、电视监控系统、数字化管理等一系列先进管理系统;为了进一步的提高中药现代化的进程,我们成立了安徽华佗现代中药研发中心,致力于中国中药现代化的研究与开发。

安徽华佗国药股份有限公司,目前具有年加工中药材5600吨的生产能力,产品有片剂、丸剂、胶囊剂、颗粒剂、单味药颗粒、中药饮片六大剂类型,60多个品种,年产值可达5.6亿元,产品大部分出口,畅销亚、欧、美三十多个国家和地区。在不久的将来,安徽华佗国药股份有限公司将成为中国最大的中成药生产企业和中药材加工基地。

在华佗国药厂的发展历史上,曾受到诸多中央和省市领导人的关心,国务院总理温家宝、副总理回良玉及安徽省历届主要党政领导人曾亲自前往华佗国药厂视察。

安徽华佗国药股份有限公司始终坚持“质量第一,诚信为本,用良心制好药”的经营理念,确保人民安全用药,保障人民身体健康,促进医药经济发展。竭诚欢迎海内外客商来厂洽谈业务,进行经贸合作。

Anhui Huatuo State Pharmaceutical Co., Ltd. is located in Bozhou City, Anhui Province, the capital of three dynasties, the hometown of Huatuo, the famous historical and cultural city of China and the first of the four major pharmaceutical capitals in China. Anhui Huatuo State Pharmaceutical Co., Ltd. has a history of more than 50 years. Its design scale and production capacity rank the top in Anhui Province, and it ranks the top in the country. In 2001, it also spent more than 100 million yuan. With reference to the advantages and characteristics of advanced Sino foreign joint ventures, the Provincial Pharmaceutical Design Institute carried out the national pharmaceutical GMP project through scientific planning, careful design, high standard construction and comprehensive implementation One time through the national GMP certification, is the first batch of domestic enterprises through GMP certification. Committed to the development of traditional Chinese medicine culture, advocating safe drug use, reassuring drug use, and adhering to the concept of "making good medicine with conscience", huatuoguo pharmaceutical factory has been focusing on quality control since the beginning. The factory is equipped with imported high-performance liquid chromatography, gas chromatograph, thin-layer scanner, violet light analyzer and other testing equipment of Shimadzu company of Japan, which can be regarded as a high starting point and a high standard of modernization Pharmaceutical manufacturing enterprises and traditional Chinese medicine processing bases. In the factory, the domestic leading full-automatic production filling line, automatic particle packaging machine, automatic capsule filling machine, automatic aluminum plastic packaging machine, automatic high-efficiency coating machine and other modern equipment are all in full compliance with the national GMP standards. In order to further improve the modernization process of traditional Chinese medicine, we have established Anhui Huatuo modern Chinese medicine research and development center, which is dedicated to the research and development of the modernization of traditional Chinese medicine. Anhui Huatuo State Pharmaceutical Co., Ltd. has an annual production capacity of processing 5600 tons of Chinese herbal medicines. Its products include six types of tablets, pills, capsules, granules, single drug granules and Chinese herbal pieces, with more than 60 varieties. Its annual output value can reach 560 million yuan. Most of its products are exported and sold well in more than 30 countries and regions in Asia, Europe and the United States. In the near future, Anhui Huatuo Guoyao Co., Ltd. will become the largest Chinese patent medicine manufacturer and Chinese herbal medicine processing base in China. In the development history of Huatuo state pharmaceutical factory, it has been concerned by many central and provincial leaders. Premier Wen Jiabao of the State Council, Vice Premier Hui Liangyu and major party and government leaders of Anhui Province have personally visited Huatuo state pharmaceutical factory. Anhui Huatuo State Pharmaceutical Co., Ltd. always adheres to the business philosophy of "quality first, integrity-based, making good medicine with conscience", so as to ensure people's safe drug use, ensure people's health and promote the development of medical economy. We sincerely welcome customers from home and abroad to come to our factory to discuss business and carry out economic and trade cooperation.

本文链接: https://brand.waitui.com/e16df2ef3.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

江波龙:员工持股平台拟合计减持公司不超1.31%股份

36氪获悉,江波龙公告,龙熹一号、龙熹二号、龙熹三号、龙舰管理、龙熹五号(统称“员工持股平台”)合计持有公司16.53%股份,计划在2025年9月11日至12月10日期间通过集中竞价交易方式和大宗交易方式合计减持公司股份不超过548万股(不超过公司总股本的1.31%)。

2小时前

云南锗业:公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划

36氪获悉,云南锗业发布股票交易异常波动公告,公司了解到,近期有国内研发机构发布了其在6英寸磷化铟外延生长工艺领域实现了技术突破相关事宜。就控股子公司鑫耀公司而言,在2-4英寸规格的磷化铟晶片量产后,为应对未来的市场需求,对更大尺寸的产品开展了研究开发,但从研发到规模化生产尚存在较大不确定性。公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划,下一步在市场与需求风险、技术风险等可控的前提下,公司方会考虑相关计划,如有相关计划,公司会按规定进行公开披露。

2小时前

胜宏科技:向香港联交所递交H股发行并上市申请并刊发申请资料

36氪获悉,胜宏科技公告,公司已于2025年8月20日向香港联交所递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请,并于同日在香港联交所网站刊登了本次发行的申请资料。该申请资料为草拟版本,其所载资料可能会适时作出更新及修订。公司本次发行尚需取得相关政府机关、监管机构、证券交易所的批准、核准或备案。

2小时前

永辉超市:上半年净亏损2.41亿元

36氪获悉,永辉超市公告,公司上半年实现营业总收入299.48亿元,同比下降20.73%;净亏损2.41亿元,上年同期盈利2.75亿元。

2小时前

摩根大通与三菱日联接近达成220亿美元的得州数据中心融资协议

英国《金融时报》周三报道,摩根大通和日本三菱日联金融集团正就为得克萨斯州一个数据中心承销220亿美元贷款展开谈判。报道称,该规划中的园区将由Vantage Data Centers所有,这是一家由银湖资本和资产管理公司DigitalBridge 控股的数字基础设施企业。报道还指出,银湖资本和DigitalBridge将合计承诺30亿美元股权,助力该数据中心园区的建设。(新浪财经)

2小时前

本页详细列出关于华佗的品牌信息,含品牌所属公司介绍,华佗所处行业的品牌地位及优势。
咨询